OPTOLANE TECHNOLOGIES INC. – Trademark Portfolio
Entity Type: 03
OPTOLANE TECHNOLOGIES INC. holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 4 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include KAIRA, DR. PCR, ON-POINT, OPTOLANE, and LOAA LAB ON AN ARRAY.
6F, 20, Pangyoyeok-ro 241beon-gil,
Bundang-gu, Seongnam-si Gyeonggi-do 13494
Showing of trademarks Trademarks
Trademark Classifications
OPTOLANE TECHNOLOGIES INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does OPTOLANE TECHNOLOGIES INC. have?
OPTOLANE TECHNOLOGIES INC. has 5 U.S. trademarks filed with the USPTO. Of these, 5 registered.
What trademark classes does OPTOLANE TECHNOLOGIES INC. file in?
OPTOLANE TECHNOLOGIES INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 9 (Computers & Electronics), Class 5 (Pharmaceuticals). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.
What are OPTOLANE TECHNOLOGIES INC.'s most well-known trademarks?
OPTOLANE TECHNOLOGIES INC.'s registered trademark portfolio includes well-known marks such as KAIRA, DR. PCR, ON-POINT, OPTOLANE, and LOAA LAB ON AN ARRAY. These are among 5 currently registered trademarks in the portfolio.
What is OPTOLANE TECHNOLOGIES INC.'s trademark registration success rate?
OPTOLANE TECHNOLOGIES INC. has a 100% trademark registration rate, with 5 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.